Riddell S, Weinerman B, Kemel S, Schipper H, Vadas G
Cancer. 1980 Sep 15;46(6):1503-8. doi: 10.1002/1097-0142(19800915)46:6<1503::aid-cncr2820460635>3.0.co;2-0.
Lymphocyte-depleted Hodgkin's Disease (LDHD) is a very aggressive form of cancer that presents at an advanced stage and for which no increase in overall survival has been demonstrated with the advent of multiple agent chemotherapy. All cases of Hodgkin's disease diagnosed in the Province of Manitoba between 1971 and 1977 were reviewed. Those cases identified as LDHD were reviewed by a single pathologist, and data was abstracted to obtain a clinical profile. Survival curves were constructed comparing the LDHD group to those with other types of Hodgkin's disease. The LDHD group was also compared with an earlier LDHD group treated with single agent chemotherapy in the 1960s. The LDHD group had a significantly shortened survival compared with the other histologies. This was just as significant when mixed cellularity Hodgkin's was compared with LDHD and matched for Stage B symptomatology. Furthermore, there was no difference in survival between the earlier LDHD groups treated with single agent chemotherapy and the later group treated with multiple agent chemotherapy.
淋巴细胞消减型霍奇金淋巴瘤（LDHD）是一种侵袭性很强的癌症，多在晚期出现，随着多药化疗的出现，其总生存率并未得到提高。对1971年至1977年间在曼尼托巴省诊断出的所有霍奇金淋巴瘤病例进行了回顾。那些被确定为LDHD的病例由一名病理学家进行回顾，并提取数据以获得临床概况。构建了生存曲线，将LDHD组与其他类型霍奇金淋巴瘤的患者进行比较。LDHD组还与20世纪60年代接受单药化疗的早期LDHD组进行了比较。与其他组织学类型相比，LDHD组的生存期明显缩短。当将混合细胞型霍奇金淋巴瘤与LDHD进行比较并匹配B期症状时，这种差异同样显著。此外，早期接受单药化疗的LDHD组与后期接受多药化疗的组在生存率上没有差异。
